ERYTECH Pharma S.A. Book Value 2011-2026 | ERYP

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value ERYTECH Pharma S.A.

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	66.8 M	26.5 M	85.6 M	146 M	181 M	35.6 M	47.1 M	35.8 M	13.6 M	-4.03 M	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
181 M	-4.03 M	63.4 M

Quarterly Book Value ERYTECH Pharma S.A.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	66.8 M	-	83.8 M	-	80.4 M	-	89.1 M	-	119 M	-	146 M	-	168 M	-	-	-	195 M	-	-	-	45 M	-	-	-	53 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
195 M	45 M	105 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Autolus Therapeutics plc AUTL	178 M	$ 1.35	-2.91 %	$ 359 M	Britain
Coherus BioSciences CHRS	61 M	$ 1.61	-3.59 %	$ 189 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Catalyst Pharmaceuticals CPRX	954 M	$ 24.88	-0.4 %	$ 3.04 B	USA
Corbus Pharmaceuticals Holdings CRBP	148 M	$ 10.02	-1.16 %	$ 133 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Cardiff Oncology CRDF	45.4 M	$ 1.57	-0.63 %	$ 105 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.65	1.3 %	$ 8.78 B	Australia
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
DBV Technologies S.A. DBVT	169 M	$ 20.25	-0.54 %	$ 2.83 B	France
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	124 M	$ 2.55	-4.14 %	$ 16 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Dyadic International DYAI	1.23 M	$ 0.87	-	$ 31.5 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Entera Bio Ltd. ENTX	6.66 M	$ 1.17	-2.1 %	$ 64 M	Israel
Equillium EQ	28.6 M	$ 2.0	-0.5 %	$ 115 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Evogene Ltd. EVGN	14.8 M	$ 0.8	2.49 %	$ 27.9 M	Israel
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Fate Therapeutics FATE	319 M	$ 1.15	-3.78 %	$ 137 M	USA
Forte Biosciences FBRX	61 M	$ 26.15	-1.1 %	$ 339 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Fennec Pharmaceuticals FENC	35.5 M	$ 6.2	-3.43 %	$ 177 M	USA
Foghorn Therapeutics FHTX	-108 M	$ 4.75	-2.59 %	$ 299 M	USA
Amicus Therapeutics FOLD	274 M	$ 14.46	0.03 %	$ 4.46 B	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
BioNTech SE BNTX	19.2 B	$ 88.37	-3.19 %	$ 27.2 B	Germany
Akari Therapeutics, Plc AKTX	28.3 M	$ 3.52	-0.56 %	$ 237 B	Britain
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Fulcrum Therapeutics FULC	349 M	$ 7.45	-4.85 %	$ 472 K	USA
Galectin Therapeutics GALT	-126 M	$ 2.38	-7.03 %	$ 152 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 315.4	-4.52 %	$ 41.3 B	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Gilead Sciences GILD	59 B	$ 138.37	-1.26 %	$ 172 B	USA
Galmed Pharmaceuticals Ltd. GLMD	36.6 M	$ 0.54	4.26 %	$ 503 K	Israel
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Genmab A/S GMAB	19.1 B	$ 27.13	-2.25 %	$ 17 B	Danmark
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA